Hepatitis Therapeutics Market Shares, Strategies and Opportunities 2024
                     Transparency  Market  Research  (TMR) has  published  a  new  report  titled  ‘Hepatitis
Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast,
2018–2026.’ According to the report, the global hepatitis therapeutics market was valued
at US$ 22,049.2 Mn in 2017 and is projected to expand at a CAGR of 2.3% during forecast
period from 2018 to 2026. The global market is anticipated to be driven by a rise in viraemic
prevalence,  promising  pipeline  of  hepatitis  drugs,  and supportive government initiatives
encouraging patients in the adoption of hepatitis drugs. The hepatitis therapeutics market in
Asia  Pacific  is  expected to  expand at  a  high  CAGR of  3.0%,  due to  a  high  incidence of
hepatitis  in  emerging  countries  such  as  India  and  China  and  presence  of  local  players
providing a wide range of generic hepatitis drugs in the region.
Request a PDF Sample 
- https://www.transparencymarketresearch.com/sample/sample.php?
flag=S&rep_id=52665
Increase in Prevalence of Viral Hepatitis Drives Market
Hepatitis is a significant public health concern across the globe. According to the World
Health Organization (WHO), in 2015, approximately, 257 million people globally, or 3.5% of
the population, were living with chronic hepatitis B infections. Rise in the consumption of
alcohol,  infections  from  contaminated  blood  sources,  and  increase  in  the  number  of
autoimmune diseases are leading to a rise in the cases of inflammation of the liver. Viral
hepatitis is an important source of morbidity and mortality globally. As per WHO estimates,
viral hepatitis caused 1.34 million deaths in 2015, a number higher than the deaths caused
by HIV. Additionally,  mortality associated with viral  hepatitis has increased by 22% since
2000, and the number is further expected to increase over the next few years. Hence, these
factors are likely to boost demand for hepatitis therapeutics over the forecast period.
Request a PDF Brochure 
- https://www.transparencymarketresearch.com/sample/sample.php?
flag=B&rep_id=52665
Hepatitis C Segment Dominated the Market
In terms of disease type, the global hepatitis therapeutics market has been classified into
hepatitis A,  hepatitis B,  hepatitis C, and others.  The hepatitis C segment is projected to
account for a leading share of the global market during the forecast period, owing to the
high  prevalence  of  hepatitis  C  in  developing  and  developed  regions  and  availability  of
effective drug regimens in the market. According to the World Health Organization (WHO),
approximately 71 million people were infected with chronic hepatitis C in 2017. Hepatitis C
increases  the risk  of  liver  cirrhosis  and is  the leading cause of  liver  transplant  in North
America and Europe. Development of advanced therapeutics by leading industry players for
the  effective  management  of  disease  is  expected  to  pave  the  way  for  the  hepatitis  C
segment over the coming years. The hepatitis B segment is projected to expand at a rapid
pace over the forecast period, owing to a high mortality rate associated with hepatitis B.
Request for Analysis of COVID19 Impact on Hepatitis Therapeutics Market- 
https://www.transparencymarketresearch.com/sample/sample.php?
flag=covid19&rep_id=52665
Multi-class Combination to be the Most Promising Segment to Invest in
Based on drug  class,  the global  hepatitis therapeutics  market  has  been segmented into
NS5A inhibitors, nucleotide analog reverse transcriptase inhibitors, multi-class combination,
nucleotide analog NS5B polymerase inhibitors, interferon & ribavirin, and others. The multi-
class  combination  segment  is  projected  to  expand  at  a  high  CAGR  during  the  forecast
period, owing to an increase in viraemic prevalence worldwide. Industry players are focused
on developing combinational  therapy as  it  is  highly  effective and has  fewer  side-effects
compared to a single regimen for the treatment of hepatitis C. Mavyret and Epclusa are
some of the combinational therapeutics recently approved by the U.S. FDA.
Asia Pacific Market to Witness Strong Growth and Create High Incremental Opportunity
In terms of region, the global hepatitis therapeutics market has been segmented into North
America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is
anticipated to account for a leading share of the global market during the forecast period,
owing  to  high  awareness  and  access  to  advanced  hepatitis  therapeutics  and  high
affordability  of  patients  in  the  region.  The  hepatitis  therapeutics  market  in  Europe  is
expected to expand at a substantial rate between 2018 and 2026. The market in Asia Pacific
is likely to expand at a rapid pace in the next few years. This is attributed to a growing
patient population, increasing penetration of global manufacturers, and rising government
initiatives to promote disease awareness in the region. The hepatitis therapeutics market in
Latin America and Middle East & Africa is anticipated to expand at a steady pace from 2018
to 2026.
Enquiry before Buying Hepatitis Therapeutics Market Report - 
https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=52665
Growth Strategies by Key Market Players
Key players profiled in this report are Merck & Co., Inc., Gilead Sciences, Inc., AbbVie Inc.,
Bristol  Myers  Squibb,  F.  Hoffmann-La  Roche,  Ltd.,  LAURUS  Labs,  Zydus  Cadila,  Hetero
Healthcare  Limited,  NATCO Pharma Limited,  and Cipla,  Inc.  Companies  operating in  the
global hepatitis therapeutics market focus on R&D to develop innovative drugs used for the
effective treatment of hepatitis. Market players also resort to strategic collaborations and
license agreements with domestic players to expand their market foothold in developing
countries.
More Trending Reports by Transparency Market Research:
https://www.globenewswire.com/news-release/2022/04/11/2420298/0/en/Revenue-of-
Diabetes-Devices-Market-to-Reach-US-73-4-Bn-by-2027-TMR-Report.html
https://www.prnewswire.com/news-releases/medical-device-technologies-market-to-
expand-at-cagr-of-4-3-during-forecast-period-notes-tmr-study-301515758.html
https://www.prnewswire.com/news-releases/fundus-cameras-market-to-reach-valuation-
of-us-810-4-mn-by-2027--says-tmr-301520905.html
About Us Section: 
Transparency Market Research is  a global  market intelligence company,  providing global
business information reports and services. Our exclusive blend of quantitative forecasting
and trends analysis provides forward-looking insight for thousands of decision makers. Our
experienced team of Analysts, Researchers, and Consultants, use proprietary data sources
and various tools  and techniques to gather,  and analyse  information. Now avail  flexible
Research  Subscriptions,  and  access  Research  multi-format  through  downloadable
databooks, infographics, charts, interactive playbook for data visualization and full reports
through MarketNgage, the unified market intelligence engine. Sign Up for a 7 day free trial!
Contact Us
Rohit Bhisey
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: [email protected]
Website: https://www.transparencymarketresearch.com/